Combined chemo-immunotherapy with liposomal drugs and cytokines
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
InventorsAlberto A. Gabizon, Eliezer Kedar, Yechezkel Barenholz
Life of this patent
Estimating the term…
Abstract
A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The cytokine is preferably also encapsulated in liposomes. In tumor models for lung and colon carcinomas, this method produced a significantly greater therapeutic effect, as evidenced by survival rate and tumor size, than a combination of the effects produced by the free or liposome-encapsulated components administered individually.
Claims20
A method for antitumor therapy, comprising
- administering to a subject in need of such treatment, a therapeutically effective amount of a non-encapsulated chemotherapy drug and an immunostimulating cytokine,
- wherein the cytokine is encapsulated in multilamellar liposomes (MLV),
- said treatment being characterized in that the subject is administered on non-consecutive days with two or more DOSES of said liposome encapsulated cytokine,
- a first dose being administered at least 3 days following administration of said chemotherapeutic drug,
- wherein the time between administrations is such that the therapeutic effect of the combined administrations is greater than the sum of the therapeutic effects produced by administration of said chemotherapeutic drug alone and by administration of said immunostimulating cytokine alone.
A method for antitumor therapy, comprising
- administering to a subject in need of such treatment, a therapeutically effective amount of a chemotherapeutic drug encapsulated in liposomes and an immunostimulating cytokine encapsulated in MLV,
- said treatment being characterized in that the subject is administered on non-consecutive days with two or more doses of said MLV encapsulated cytokine,
- a first dose of said MLV encapsulated cytokine being administered at least 3 days following administration of said liposome encapsulated chemotherapeutic drug,
- wherein the time between administration of said MLV encapsulated chemotherapeutic drug and said liposome encapsulated cytokine is such that the combined therapeutic effect of said administrations is greater than a sum of the therapeutic effect produced by administration of the liposome encapsulated chemotherapeutic drug alone by administration of said MLV encapsulated immunostimulating cytokine alone.
Dependencies are inferred from the claim text.